JINGHUA PHARM: Ritonavir has received approval for the listing application of chemical raw materials
JINGHUA PHARM announced that its subsidiary Nantong Company has obtained approval from the National Medical Products Administration for the marketing application of Ritonavir chemical raw materials. This antiviral drug is primarily used for the treatment of AIDS and has also been widely used during the COVID-19 pandemic. This approval means that the raw materials meet national review standards and can be produced and sold in the domestic market in the future, enhancing the company's competitiveness in the field of chemical raw materials
According to the Zhitong Finance APP, JINGHUA PHARM (002349.SZ) announced that its subsidiary, JINGHUA PHARM Group Nantong Co., Ltd. (hereinafter referred to as "Nantong Company"), has received the approval notice for the listing application of Ritonavir raw materials issued by the National Medical Products Administration.
Ritonavir raw materials are downstream raw material extensions of the Ritonavir pharmaceutical intermediates produced by Nantong Company. It is an antiviral drug primarily used for the treatment of AIDS. During the COVID-19 pandemic, Ritonavir was also one of the main drugs used for treating COVID-19.
The approval of Ritonavir's listing application indicates that this raw material has met the relevant technical standards for raw material review in the country. After complying with the requirements of Good Manufacturing Practice (GMP), it can be produced and sold in the domestic market, which is beneficial for expanding the product's sales in the domestic market and enhancing the company's market competitiveness in the field of chemical raw materials
